More information: Rita C. Acúrcio et al, Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering RNA (siRNA) platform. The partnership gives ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often ...

AbbVie is entering a collaboration and license option deal with ADARx Pharmaceuticals to develop a new type of RNA technology for disease areas like neuroscience, immunology and oncology.

Functional cure of chronic hepatitis B (CHB) remains a major clinical challenge. Current therapies—including nucleos(t)ide analogs, interferon, siRNA, and therapeutic vaccines—often fail to ...